Printing.com cautiously optimistic
High street printing services firm Printing.com said half year pre-tax fell but while it remains cautious about future prospects, it is well placed for growth.
High street printing services firm Printing.com said half year pre-tax fell but while it remains cautious about future prospects, it is well placed for growth.
For the six months ended 30 September turnover increased to £10.73m from £7.1m the year before. Pre-tax profit for the period fell to £0.50m from £0.62m previously. EBITDA rose to £1.5m from £1.31m.
Printing.com has declared an interim dividend of 1.05p per share, unchanged from last year.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Diluted EPS fell to 0.80p from 1p in 2010. Net cash reduced to £0.96m from £1.61m in 2010.
Commenting on current trading the group said, "Across the UK and Ireland trading remains soft. Conversely trading across the Netherlands and Belgium continues to exceed our expectation."
Printing.com said the challenge now, across all of the new channels, is to achieve the necessary scale in an expeditious manner whilst generating a positive contribution as soon as is practicable.
"Given the present economic uncertainty coupled with the many new channel launches, the Board is appropriately cautious in the short term but, moving forward remains optimistic about prospects."
--
cj
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published